Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
NCT Number: NCT04620486
The objective is to compare the timeliness of anchor antibiotic administration in the emergency department (ED) after initial dosing with and without a Best Practice Alert in Epic (BPA) implemented to remind physicians to re-order the antibiotic.
We hypothesize that post-BPA implementation, physicians will have a higher rate of ordering subsequent doses of antibiotics on-time and with the correct dosages compared to pre-BPA implementation.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02114, United States
Antibiotics administration can sometimes be delayed in the emergency department (ED) environment, where antibiotics are frequently ordered in electronic medical record systems as a one-time dose and the second dose is delayed or missed. This has been described in the literature, a 2017 article in Critical Care Medicine noted in a single academic center that 33% of sepsis cases had 2nd-dose-antibiotic delays greater than 25% of the recommend interval and this was associated with significantly increased hospital mortality (OR 1.61) and mechanical ventilation (OR 2.44).
An Epic Best Practice Advisory (BPA) was created by the Mass General Brigham eCare Decision Support team to address this patient safety concern. The BPA alerts providers in the ED or ED Observation when the next dose of broad-spectrum antibiotic dose is due for a patient if no future administration has been ordered, based on patient characteristics (such as renal function) and antibiotic selection. The objective of this study is to analyze the impact of this BPA on our performance in terms of on-time antibiotics through a randomized controlled trial. Patients whose medical record number (MRN) are odd will be assigned to the treatment group, while those whose MRNs are even will be assigned to the control group. The BPA will only be displayed to the patient's providers for the treatment group. We will then compare the performance of on-time antibiotics between the groups and the resulting impact on patient outcomes, such as overall hospital length of stay, admission to the intensive care unit (ICU), and in-hospital mortality.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is a customized Best Practice Alert created at Mass General Brigham in the institutional Epic electronic medical record system.
Time frame: Between 0 and 24 hours after expected antibiotic re-administration
The length of delay between time of expected antibiotic re-administration and the actual time of antibiotic re-administration
Time frame: Through study completion, up to 1 year
Number of days that patient is hospitalized
Time frame: Through study completion, up to 1 year
Whether a patient received care in the Intensive Care Unit (ICU) during hospital admission
Time frame: Through study completion, up to 1 year
Whether a patient received died during hospital admission
Massachusetts General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05752019
Bacterial Infections, Bacterial Infections and Mycoses
Rotterdam, South Holland, Netherlands
View Trial DetailsNCT06694844
Alveolar Ridge Preservation, Bacterial Infections
Rijeka, Croatia
View Trial DetailsNCT02339155
Bacterial Infections, Bacterial Infections and Mycoses
Edgewater, Florida, United States
View Trial DetailsNCT04493931
Bacterial Infections, Bacterial Infections and Mycoses
Las Vegas, Nevada, United States
View Trial Details